↓ Skip to main content

ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria

Overview of attention for article published in Clinical and Translational Allergy, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)

Mentioned by

twitter
11 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria
Published in
Clinical and Translational Allergy, August 2015
DOI 10.1186/s13601-015-0072-9
Pubmed ID
Authors

Karsten Weller, Marcus Maurer, Clive Grattan, Alla Nakonechna, Mohamed Abuzakouk, Frédéric Bérard, Gordon Sussman, Ana M. Giménez-Arnau, Javier Ortiz de Frutos, André Knulst, G. Walter Canonica, Kelly Hollis, Doreen McBride, Maria-Magdalena Balp

Abstract

Chronic spontaneous urticaria (CSU) formerly known as chronic idiopathic urticaria (CIU) is a severe and distressing skin condition that remains uncontrolled in approximately one half of patients, despite the use of licensed, recommended doses of modern, second-generation H1-antihistamines. So far, the humanistic, societal and economic burden of CSU/CIU has not been well quantified. Therefore it is important to broaden our understanding of how CSU/CIU impacts patients, society, and healthcare systems, by determining the disease burden of CSU/CIU and the associated unmet need; as well as to further guide the use of new treatments in an efficient and cost-effective manner. ASSURE-CSU is an observational, multicenter study being conducted in the UK, Germany, Canada, France, Italy, Spain, and The Netherlands. The study comprises a retrospective medical chart review in conjunction with patient surveys (including validated tools for assessment of disease impact) and an 8-day patient diary. The primary objectives of the study are to describe patient demographics, medical history, treatments, and healthcare resource utilization based on medical-record data and to assess the impact of disease, healthcare resource utilization, work days missed, and productivity loss based on patient-reported data. Approximately 700 patients (aged ≥18 years) will be enrolled who have CSU/CIU despite currently receiving treatment, and have had persistent symptoms for at least 12 months. Data will be collected retrospectively for the 12 months (±1 month) prior to enrolment wherever possible, and prospectively for the week following enrolment. ASSURE-CSU will be the first study to examine the economic and humanistic burden of disease in patients diagnosed with CSU/CIU who are symptomatic despite treatment. By combining retrospective evaluation of medical records with prospective patient surveys and 8-day diaries, across seven different countries, the ASSURE-CSU study will contribute to a better understanding and acknowledgement of the burden of disease in patients with symptomatic chronic spontaneous urticaria.

Twitter Demographics

The data shown below were collected from the profiles of 11 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Korea, Republic of 1 3%
United States 1 3%
Unknown 38 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 18%
Student > Master 6 15%
Other 5 13%
Student > Postgraduate 4 10%
Student > Bachelor 3 8%
Other 9 23%
Unknown 6 15%
Readers by discipline Count As %
Medicine and Dentistry 19 48%
Agricultural and Biological Sciences 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Social Sciences 2 5%
Immunology and Microbiology 2 5%
Other 4 10%
Unknown 8 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2016.
All research outputs
#2,776,985
of 15,295,300 outputs
Outputs from Clinical and Translational Allergy
#181
of 466 outputs
Outputs of similar age
#48,615
of 240,328 outputs
Outputs of similar age from Clinical and Translational Allergy
#1
of 1 outputs
Altmetric has tracked 15,295,300 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 466 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,328 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them